Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
Table 5
Evolution of BCVA in subgroup of patients that completed at least 5 years of follow-up.
Timepoint
Visual acuity
Year
Month
n
BCVA, mean (LogMAR) ± SD
BCVA change from baseline, mean (LogMAR) ± SD
value
0
55
0.74 ± 0.61
—
—
3
55
0.73 ± 0.59
−0.01 ± 0.41
0.9228
6
55
0.68 ± 0.59
−0.06 ± 0.46
0.3548
1
12
55
0.69 ± 0.56
−0.05 ± 0.52
0.5114
18
54
0.67 ± 0.51
−0.07 ± 0.49
0.3014
2
24
54
0.73 ± 0.63
−0.01 ± 0.48
0.8651
30
54
0.73 ± 0.48
−0.02 ± 0.46
0.7739
3
36
55
0.81 ± 0.65
0.08 ± 0.49
0.2489
42
54
0.77 ± 0.53
0.03 ± 0.53
0.6794
4
48
54
0.74 ± 0.48
0.00 ± 0.50
0.9708
54
53
0.79 ± 0.60
0.06 ± 0.57
0.4329
5
60
55
0.76 ± 0.56
0.02 ± 0.57
0.7782
Note. n = 55 patients completed at least 5 years of follow-up; 28/55 (50.9%) treatment-naïve, 27/55 (49.1%) previously treated. value for BCVA change at different timepoints in comparison to baseline BCVA.
